Findings

What do systematic reviews say?

5 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 5 · 83.3%High 0 · 0%

Budesonide 3 mg vs placebo

Clinical remission · Patients with active Crohn's disease

Budesonide 3 mg showed no clear difference in induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (low certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.67 [0.92, 3.02]
1 study · 133 participants
Low

Budesonide 9 mg vs steroids

Clinical remission · Patients with active Crohn's disease

Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 0.85 [0.75, 0.97]
8 studies · 750 participants
Moderate

Budesonide 9 mg vs placebo

Clinical remission · Patients with active Crohn's disease

Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.93 [1.37, 2.73]
3 studies · 379 participants
Moderate

Budesonide 15 mg vs placebo

Clinical remission · Patients with active Crohn's disease

Budesonide 15 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 2.25 [1.35, 3.76]
2 studies · 181 participants
Moderate

Budesonide 9 mg vs mesalamine

Clinical remission · Patients with active Crohn's disease

Budesonide 9 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeksThomsen 1998 compared with mesalamine (moderate certainty).

2 findings from 1 review

Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.63 [1.23, 2.16]
1 study · 182 participants
Moderate
Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
RR 1.12 [0.95, 1.32]
1 study · 307 participants
Moderate